Qu Biologics has developed a transformative first-in-class immunotherapy platform, Site Specific Immunomodulators (SSIs), that arms our first line of defense against infectious and non-infectious threats. SSIs are uniquely positioned to be implemented at the time of first emergence of a novel viral strain to be used both prophylactically and therapeutically.
Qu Biologics is seeking funding/collaboration/partnership to rapidly progress QBKPN and its transformational potential into Phase 2 (randomized controlled trial in COVID-19 high risk group).
Additional Qu Biologics Testimonials Around Proposed Covid-19 Trial:
Dr. Simon Sutcliffe (MD, FRCP, FRCR, FRCPC)
Past President & CEO, BC Cancer Agency (British Columbia, Canada)
Dr. Hal Gunn
CEO (Qu Biologics Inc.)
Dr Hal Gunn, CEO of Qu Biologics, Vancouver, BC, Canada, along with co-founder Rob Freeman were interviewed by Dahlia Kurtz of AM Radio 580 Ottawa, Canada, about the proposed COVID-19 clinical trial:
PDF Powerpoint / Slideshow – “Harnessing the Power of Innate Immunity: First Line of Defense Against Viral Infection”:
Qu Biologics:
